747 related articles for article (PubMed ID: 27782084)
21. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
Packiriswamy N; Upreti D; Zhou Y; Khan R; Miller A; Diaz RM; Rooney CM; Dispenzieri A; Peng KW; Russell SJ
Leukemia; 2020 Dec; 34(12):3310-3322. PubMed ID: 32327728
[TBL] [Abstract][Full Text] [Related]
22. [Synergistic Effect of NF-κB Signaling Pathway Inhibitor and Oncolytic
Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms].
Xia M; Meng G; Dong J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):245-253. PubMed ID: 33775041
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.
Li H; Peng KW; Russell SJ
Hum Gene Ther; 2012 Mar; 23(3):295-301. PubMed ID: 22235810
[TBL] [Abstract][Full Text] [Related]
25. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
28. Heat shock protein inhibitors increase the efficacy of measles virotherapy.
Liu C; Erlichman C; McDonald CJ; Ingle JN; Zollman P; Iankov I; Russell SJ; Galanis E
Gene Ther; 2008 Jul; 15(14):1024-34. PubMed ID: 18356818
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic measles virus strains as novel anticancer agents.
Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
[TBL] [Abstract][Full Text] [Related]
31. Measles virus as an oncolytic vector platform.
Blechacz B; Russell SJ
Curr Gene Ther; 2008 Jun; 8(3):162-75. PubMed ID: 18537591
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.
Li H; Peng KW; Dingli D; Kratzke RA; Russell SJ
Cancer Gene Ther; 2010 Aug; 17(8):550-8. PubMed ID: 20379224
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
35. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
[TBL] [Abstract][Full Text] [Related]
36. Measles virus for cancer therapy.
Russell SJ; Peng KW
Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
[TBL] [Abstract][Full Text] [Related]
37. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR
Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of oncolytic measles virus: promises and challenges.
Galanis E
Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
[TBL] [Abstract][Full Text] [Related]
39. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763
[TBL] [Abstract][Full Text] [Related]
40. A measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.
Fujiyuki T; Yoneda M; Amagai Y; Obayashi K; Ikeda F; Shoji K; Murakami Y; Sato H; Kai C
Oncotarget; 2015 Sep; 6(28):24895-903. PubMed ID: 26317644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]